Abstract 244P
Background
Managing head and neck squamous cell carcinoma (HNSCC) requires a prolonged course of concurrent chemoradiotherapy and other supportive care measures. Such a multidisciplinary approach was significantly hampered during the emergence of the COVID-19 pandemic which necessitated divergence of health resources towards treating the infected patients thereby compromising cancer care. Therefore, we adopted an alternate-day hypofractionated radiotherapy (ADH RT) schedule, aiming to decrease patients’ hospital visits daily without compromising the oncological outcomes. This study assesses the response and toxicity of the ADH RT schedule in HNSCC patients.
Methods
Retrospective analysis of all histopathologically proven HNSCC patients treated with ADH RT regimen during April – October 2020 in our institute. Hypofractionation dose schedule: 63Gy/21 fractions, 3Gy/fraction was delivered on alternate days without concurrent chemotherapy after patients' consent. Weekly radiation toxicity assessment and post-radiotherapy response assessment by CECT face and neck at 3 and 6 months.
Results
A total of 26 patients were planned for ADH RT. Most (96%) of them were males with a median age of 60 years and ECOG PS ≤2. The most common tumor site was the oropharynx (58%), the stage was IVA (54%) followed by stage IVB (27%). 93% of patients had a history of tobacco smoking. Only 23 patients completed the treatment and were included in the final assessment. Mucositis and dermatitis grade 1, 2 and 3 was observed in 44%, 52%, 4% and 78%, 18%, and 4% patients, respectively. At three months of follow-up, 5 patients were lost to follow-up and 4 patients expired due to COVID/disease-related complications. Complete response (CR) was observed in 10 patients (71.4%) and partial response in 4 patients. At 6 months, CR was observed in 7 (64.5%) patients.
Conclusions
Most of the patients were able to tolerate and complete treatment. At analysis, around half of the patients either expired or were lost to follow-up which is the major limitation of this study. Among the available patients, a good response was observed. The practical applicability of this regimen needs to be tested further with a larger sample size and longer follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - Short course brachytherapy in locally advanced cervical cancer: Safety and response rate
Presenter: Maryam Garousi
Session: Poster viewing 03
197P - The risk of uterine cervical cancer in inflammatory bowel disease: An updated systematic review and meta-analysis
Presenter: Hee Man Kim
Session: Poster viewing 03
198P - Geographic and demographic access to brachytherapy in India, with a special emphasis on gynaecological cancers
Presenter: Abhishek Krishna
Session: Poster viewing 03
199P - Prevalence of cervical cancer in Uzbekistan: A population based study
Presenter: Sayde Djanklich
Session: Poster viewing 03
200P - A retrospective institutional analysis on gynecological malignant mixed Mullerian tumors
Presenter: Monik Patel
Session: Poster viewing 03
201P - Immunotherapy in advanced mismatch repair deficiency endometrial cancer: A real-world single center experience
Presenter: Amit Rauthan
Session: Poster viewing 03
203TiP - Autophagy as a target for therapy in ovarian cancer: A phase II randomized trial with biomarker correlation (ATOC Trial)
Presenter: Luxitaa Goenka
Session: Poster viewing 03
210P - Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
Presenter: Lei Chen
Session: Poster viewing 03
211P - Chemotherapy delivery time affects anti-lymphoma treatment outcome in a sex-dependent manner
Presenter: Yeonsoo Park
Session: Poster viewing 03